Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
26°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marinus Pharma CS
(NQ:
MRNS
)
1.410
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
12,161
Open
1.410
Bid (Size)
1.300 (21)
Ask (Size)
1.340 (36)
Prev. Close
1.410
Today's Range
1.410 - 1.410
52wk Range
1.110 - 11.26
Shares Outstanding
54,642,580
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
April 17, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss
April 16, 2024
Marinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review.
Via
Benzinga
Performance
YTD
-86.44%
-86.44%
1 Month
-84.84%
-84.84%
3 Month
-85.52%
-85.52%
6 Month
-79.14%
-79.14%
1 Year
-82.55%
-82.55%
More News
Read More
The Latest Analyst Ratings For Marinus Pharma
April 16, 2024
Via
Benzinga
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
April 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
April 15, 2024
Via
InvestorPlace
Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights
March 26, 2024
Via
Benzinga
Leverage Shares -3x Short Moderna (MRNA) ETP Securities: Q4 Earnings Insights
March 05, 2024
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
April 15, 2024
Via
Benzinga
Why Are Stocks Up Today?
April 15, 2024
Via
InvestorPlace
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
April 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
DJT Stock Alert: Trump Media Plunges on Share Sale Panic
April 15, 2024
Via
InvestorPlace
Topics
Government
Exposures
Political
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
April 15, 2024
Via
InvestorPlace
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
April 15, 2024
From
Schall Law
Via
GlobeNewswire
Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?
April 15, 2024
Via
Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
April 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 15, 2024
Via
Benzinga
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
April 15, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
March 27, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q4 2023
March 05, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 05, 2024
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Earnings Scheduled For March 5, 2024
March 05, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.